Reported total revenue of $102.3 million with 27% year-over-year growth in exome and genome revenue Reported exome and genome volume growth of 34% year-over-year Reported adjusted gross margin (1) of 69% and adjusted net loss (1) of $8.2 million Updating full-year 2026 revenue guidance to $475 to
GAITHERSBURG, Md. --(BUSINESS WIRE)--Apr. 13, 2026-- GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced it will release financial results for the first quarter of 2026 after the market closes on Monday, May 4, 2026.
New data shows up to 61% reduction in healthcare costs for children with neurodevelopmental disorders in the 12 months following ExomeDx™ and GenomeDx™ testing, regardless of the test result GAITHERSBURG, Md.--( BUSINESS WIRE)-- GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and
Program to expand access to exome sequencing to help clinicians confirm diagnosis and guide clinical decision-making in NPC GAITHERSBURG, Md. --(BUSINESS WIRE)--Mar. 10, 2026-- GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today
GeneDx showcases leadership in exome and genome quality, expanded access through non-genetics ordering, and AI-driven innovations that enhance speed, scale, and diagnostic impact GAITHERSBURG, Md. --(BUSINESS WIRE)--Mar. 9, 2026-- GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and
GAITHERSBURG, Md. --(BUSINESS WIRE)--Feb. 25, 2026-- GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced that company management will participate in upcoming investor conferences: TD Cowen 46th Annual Health Care
Reported fourth quarter 2025 revenues of $121.0 million with 32% year-over-year growth in exome and genome test revenue (42% excluding a one-time 2024 benefit) Accelerated exome and genome volume growth to 34% year-over-year Reported fourth quarter 2025 adjusted gross margin 1 of 71% Reported
Recognition highlights growing global impact of rare disease diagnosis and the role of genomics in transforming health outcomes GAITHERSBURG, Md. --(BUSINESS WIRE)--Feb. 11, 2026-- GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data,
GAITHERSBURG, Md. --(BUSINESS WIRE)--Feb. 3, 2026-- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced it will release financial results for the fourth quarter of 2025 before the market opens on Monday, February 23, 2026.
Expects full year 2025 revenues of $427 million , with exome and genome revenue up 54% (58% excluding a one-time 2024 benefit) Expects fourth quarter 2025 revenues of $121 million , with exome and genome revenue up 32% (43% excluding a one-time 2024 benefit) Expects full year 2025 exome and genome